LATEST NEWS
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
REWATCH: Nanobiotix Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

ABOUT US

About Us - text graphic

Pioneers in nanomedicine

For more than two decades, we have pushed past the frontiers of nanomedicine to expand therapeutic possibilities for patients around the world. Building upon a French legacy of spearheading breakthroughs in medicine, our physics-based approach to therapeutics has enabled the discovery of novel treatments with disruptive potential.1

Our team is united by the ethos that developing a cure for cancer that can help millions of patients around the world demands thoughtful exploration beyond existing scientific frontiers. Dedicated and driven, we take pride in delivering cutting-edge, effective treatments to patients and value to our stakeholders.

Leadership

Laurent Levy, PhD
Chief Executive Officer
Anne-Juliette Hermant
Anne-Juliette Hermant
Chief People Officer
Louis Kayitalire, MD
Chief Medical Officer
Bart Van Rhijn
Chief Financial and Business Officer
Anne-Sophie Larivière
Vice President, Strategy & Operational Excellence
Brandon Owens
Vice President, Strategic Marketing and Corporate Communications
Craig West
SVP, Investor Relations

Supervisory Board

Gary M. Phillips, MD
Chairman
Alain Herrera, MD
Independent Member
Enno Spillner
Independent Member
Anne-Marie Graffin
Vice-Chairwoman

Scientific Advisory board

Sylvie Bonvalot, MD, PhD, HDR
Sylvie Bonvalot, MD, PhD, HDR
Surgical Oncologist
Curie Institute (France)
Jean Bourhis, MD, PhD
Jean Bourhis, MD, PhD
Radiation Oncologist
Lausanne University Hospital (Switzerland)
Stéphane Champiat, MD, MS, PhD
Stéphane Champiat, MD, MS, PhD
Medical Oncologist
Gustave Roussy (France)
Thierry De Baère, MD
Thierry De Baère, MD
Interventional Radiologist
Gustave Roussy (France)
Robert L. Ferris, MD, PhD, FACS
Robert L. Ferris, MD, PhD, FACS
Surgical Oncologist
University of Pittsburgh Medical Center (US)
Silvia Chiara Formenti, MD, FASTRO
Silvia Chiara Formenti, MD, FASTRO
Radiation Oncologist
NewYork-Presbyterian/Weill Cornell Medical Center (US)
Nancy Y. Lee, MD, FASTRO
Nancy Y. Lee, MD, FASTRO
Radiation Oncologist
Memorial Sloan Kettering Cancer Center (US)
Christophe Le Tourneau, MD, PhD
Christophe Le Tourneau, MD, PhD
Medical Oncologist
Curie Institute (France)
Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS
Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS
Surgical Oncologist
University Hospital Birmingham (UK)
Chiaojung Jillian Tsai, MD, PhD
Chiaojung Jillian Tsai, MD, PhD
Radiation Oncologist
Princess Margaret Cancer Centre (Canada)
Jared Marc Weiss, MD
Jared Marc Weiss, MD
Medical Oncologist
University of North Carolina (US)
Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
Clinical Oncologist
Royal Marsden Hospital
Nabil F. Saba, MD, FACP
Medical Oncologist
Emory University (US)

Key Figures

More than 350 patients have been injected with NBTXR3
+ 0
More than 400 health care providers are involved in Nanobiotix clinical trials
+ 0
More than 400 patents were issued or are in the process of being issued
+ 0

Become part of the Nanobiotix team

Explore Careers

Reference: 1. Foray N. Victor Despeignes, the forgotten pioneer of radiation oncology. Int J Radiat Oncol Biol Phys. 2016;96(4):717-721. doi:10.1016/j.ijrobp.2016.07.019

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.

CONTACT US